Science Articles

Polisorb For Food & Drug Allergy Responses in Children and Adults

Zhakov Ia.I. (2007) used Polisorb MP in the early age pathology unit (35 children), in the gastroenterological unit (22 children) and serum unit (34 children) of the children's hospital. In the early age pathology unit, the course of administration with Polisorb MP was mainly received by children with acute allergic reactions (19 people) and intestinal dysbacteriosis (16 people). The results obtained allow for the conclusion that the enterosorbent Polisorb MP is a highly effective medication for the treatment of allergic diseases associated with food hypersensitivity, as well as intestinal dysbacteriosis [35].

101 children aged 2 to 7 years were examined by Stepanov O. G. et al. (2000). The observations show that Polisorb therapy exhibits the most prominent positive effect in the treatment of acute cases of food allergy, especially in patients with gastroenterological pathology combined with dysbiotic changes (shortening the hospitalization period by 3.8 days compared to children not receiving Polisorb). Other findings demonstrate the high efficiency of Polisorb in terms of opportunistic flora (isolation rate decrease in 70% of the cases) and E. coli with modified properties (43%) [36].

Khasanova R.B. (1997) included Polisorb MP in conventional treatment regimens for 28 patients with drug allergies. The control group consisted of 20 patients with drug allergies. Polisorb MP was prescribed for drug allergies from 5 to 15 days, depending on the severity of the clinical manifestations. Polisorb MP was the only medication for these patients in combination with fasting dietary treatment for a period of three days. With recurrent angioedema along with Polisorb MP, prednisolone was introduced into the treatment regimen at a dosage of 0.5 mg per 1 kg of the patient's body weight in a decreasing regiment for five days. The recovery of eosinophils in the blood was determined for 4.5 ± 0.3 days (in the control after 7.8 ± 0.7 days) when analyzing laboratory findings. A statistically significant decrease in the IgE level was recorded in patients from the main group (p <0.05) in patients with drug allergy in the Polisorb MP group before discharge from the hospital. According to the results of the research, the authors documented and confirmed the high efficiency of the use of the medication Polisorb MP in urticaria, drug fever and eosinophilia [37]. 

Novikova L.A. et al. (2011) investigated the effectiveness of the complex therapy of toxicodermia using the enterosorbent Polisorb MP. The study included 36 patients with toxicodermia, 20 women and 16 men. The etiological factor was the intake of medications in 22 patients, including 6 - penicillin, 4 - ampicillin, 4 - erythromycin, 4 – biseptol and 4 - doxycycline. Food toxicodermia was reported in 10 patients and inhalation of dyes was the etiological factor in 4 patients. In the clinical picture, bullous eruptions were found in 4 patients, in 6 patients - vesicular eruptions, in 12 patients - papular eruptions and in 14 patients - erythematous squamous eruptions. Blood count parameters were determined with the calculation of Kalf-Kalifa leukocyte index of intoxication and level of medium molecular weight peptides. A leukocytosis reaction with medications was performed in 22 patients. Drug therapy was carried out with hyposensitizing agents — antihistamines. Polisorb MP was prescribed at a dose of 150-200 mg / kg / day (7-20 g per day). The sorbent was taken in the form of an aqueous suspension one hour before meals. The daily dosage was divided into three dosages. The duration of treatment was 5-10 days. All patients showed positive clinical dynamics expressed in a decrease in the area and intensity of inflammatory response of the skin. The use of the medication Polisorb MP in patients with toxicodermia caused a decrease in itching, the disappearance of vesicular and bullous, and deflorescence of spotted and papular eruptions. Prescription of Polisorb MP led to positive dynamics of endogenous intoxication indicators (leukocyte index of intoxication, medium-weight molecules), reduced the amount of drug therapy, and reduced the duration of treatment [38].

Ugleva T.N. et al. (1997) has studied the efficiency of Polisorb in 80 children aged from 1 month to 15 years with eczema and neurodermatitis and other skin allergological diseases in the acute stage at the Children's Clinical Hospital. Polisorb was administered upon admission as the first therapy course. In some children, in cases of disease recurrence, repeated courses were used after a period of 2-3 weeks. The research results demonstrated high efficiency of using Polisorb in children suffering from skin diseases. Positive changes were observed in the majority of patients – as a decrease of hyperemia and infiltration in the skin and lesser severity of itching and oozing. The most significant clinical effect was observed in children with a short history of eczema and in the case of diffuse neurodermitis characterized by generalized skin lesions, long-term disease history, by the presence of polyvalent allergy and multi-organ lesions. The authors also noted the normalization of the frequency and nature of the bowel movement in patients using the medication Polisorb MP. The achieved positive clinical results persisted after discontinuation of the medication in the settings of following the hypoallergenic diet. In the majority of patients, improvements were observed in the results of feces analysis: decreased isolation rate and the number of opportunistic microflora and better survivability of bifido- and lactobacteria in cases of taking bacterial drugs [39].

The research conducted by Malikova M.S. (2013) included 40 patients of both genders aged 7 to 57 years with the following diagnoses: topic dermatitis of moderate severity– 20 patients (50%) and acute or recurrent urticaria - 20 patients (50%). The effectiveness of therapy was evalauted using the Scoring Atopic Dermatitis Index (SCORAD), according to which a higher score corresponds to a more severe disease severity. Before treatment the mean SCORAD scores in the main group of atopic dermatitis patients to the moment of treatment initiation was 47.3, while in the control group – 46.5 points. The decrease in the intensity of hyperemia, swelling, infiltration and itching in the main group was observed on the 6-7th treatment day (6.5 days), while in the control group – on the 9-10th treatment day (9.6 days). The SCORAD scores at the end of the first week were 30.2 and 36.4 points, respectively. By the end of the second week of treatment in patients from the main group, hyperemia and edema disappeared and the severity of infiltration and itching significantly decreased, but dry skin and peeling remained. In patients from the control group, hyperemia and infiltration persisted and itching was of moderate intensity. By the end of the second week of treatment, remission in the main group was found in 7 patients (70%), incomplete remission (remaining moderate skin dryness and exfoliation) – in 2 patients (20%) and one patient (10%) had persistent moderate itching. The SCORAD scores by the 14th day were 9.5. In patients with urticaria, the pruritis after using Polisorb persisted for 1.9 days, while in the patients of control group it persisted for 3.6 days; the urticaria elements in the main group persisted for 5.8 days with 9.1 days in the second group; the repeated rash onsets in the main group were found in 3 patients (30%) with 6 patients in the control group (60%) [40]. 

Bondar S.A. et al. (1992) conducted research which included 250 patients with eczema and 160 patients with psoriasis. As a result of the conducted comprehensive treatment, recovery was observed in 71% of patients with eczema and in 53% of patients with psoriasis, significant improvement was observed in 22% and 30%, respectively, improvement - in 5% and 17%, respectively and no changes were observed in 1% of patients, deterioration - at 1%. After the treatment, a decrease in the level of EMS was found: 0.289 ± 0.025 patients with eczema and 0.327 ± 0.018 in patients with psoriasis in the remission phase. There was a decrease in sorption capacity of red blood cells in patients with eczema to 38.1 ± 1.57%. Significantly higher indicators were found in the parameters of cellular and humoral immune response, in the activity of catalytic properties of myeloperoxidase and succinate dehydrogenase within the blood corpuscle, which indicates the applicability of introducing enterosorption therapy with Polisorb into the practical dermatological service for debridement of patients with eczema and patients with psoriasis. The authors also noted the high efficiency of Polisorb MP in the treatment of allergic state, including allergic dermatoses [41]. 

Pyatnitskaya S.A. et al. (2010) examined 100 children of both genders aged from 6 months to 15 years with the following diagnoses: acute or recurrent urticaria, atopic dermatitis and impaired purine metabolism with acetonemic vomiting. The authors selected 2 groups of children. Patients from the first group (n = 60) received Polisorb MP and children from the second group (n = 40) received other enterosorbents (Enterosgel®, activated charcoal). In patients with urticaria, the duration of persisting pruritus was statistically significantly lower in the course of therapy with Polisorb MP (1.7 days versus 3.4 days in patients from group 2, p <0.05), as well as the duration of preservation of urticaria skin elements (6.4 days versus 8.8 days, p <0.05), and the duration of eosinophilia (5.2 days versus 7.6, p <0.05). When discharging patients with atopic dermatitis the average value of the SCORAD scores decreased to a greater extent in children under Polisorb MP - from 58.7 to 43.2, while the value of this indicator decreased from 57.5 to 50.4 without the use of Polisorb MP. Eosinophilia duration in the course of therapy with Polisorb MP was lower - 7.8 days versus 9.1 days without the use of Polisorb MP (p <0.05). Thus, when using the medication Polisorb MP in children with urticaria, atopic dermatitis and purine metabolism disorders, faster resolving of disease symptoms and the normalization of the laboratory research methods results were reported, in addition, the use of the medication Polisorb MP shortens the hospitalization period for children [42].

Mitkovskaya O. A. (2014) in an open-label prospective comparative research studied the effectiveness of the use of the medication Polisorb MP for the treatment of allergic diseases in patients aged 15-50 years with moderate atopic dermatitis during a period of exacerbation. With a background of therapy with the studied medication, the author revealed an improvement in patients’ health, recovery of a normal lifestyle, a decrease in the pruritus and eruptions severity in 85% of patients and a decrease in the number of eosinophils in the blood and the level of interleukin (IL) -5, IL-4. No serious exacerbation of atopic dermatitis was observed when patients were under supervision for the period of 1 month after undergoing treatment [43].